Welcome, Guest
Username: Password: Remember me
CYTX Financial performance development
  • Page:
  • 1
  • 2

TOPIC: A Magical Mystery Tour- Part II?

A Magical Mystery Tour- Part II? 16 Mar 2016 07:16 #6648

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115
From the CC and from Marc Hedrick´s prepared statement-

So to show full compliance we will need to regain the dollar bid price for 10 days prior to May 31. Now realistically, there are only two ways to do that.
Plan A is organic appreciation, that’s obviously preferable, and we did that last spring. We think it’s possible to do that again, but we need a Plan B.


This statement really bugs me like crazy- how can a conservative MD, who happens to be CEO of Cytori come up with this humbug? I think we owe it it ourselves, to evaluate the chances i.e. this part- we did that last spring. We think it’s possible to do that again

In order to assess that in kind of a minimax model- we need combined intelligence, of chart and market junkies, of behavioural science experts, fundamentalists, and realists amongst us. i.e. we need first to understand what happened last year and after that, project that on the 7-8 weeks that we have left until the Shareholders meeting to assess the chances of a Part II of the Magical Mystery Tour recurring... :KO: :write:


Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

A Magical Mystery Tour- Part II? 16 Mar 2016 07:31 #6649

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115
First the facts from last spring - this is the chart for approx. 3-4 month period when the Magical Mystery Tour was happening between February and May 2015:



Thereto - volumes from Yahoo historical Prices-

Date Open High Low Close Volume Adj Close*
May 12, 2015 0.74 0.74 0.69 0.72 2,634,500 0.72
May 11, 2015 0.76 0.78 0.69 0.71 3,297,700 0.71
May 8, 2015 0.71 0.75 0.69 0.73 2,212,000 0.73
May 7, 2015 0.71 0.72 0.68 0.69 2,781,100 0.69
May 6, 2015 0.79 0.79 0.71 0.71 1,800,200 0.71
May 5, 2015 0.84 0.85 0.70 0.71 9,915,600 0.71
May 4, 2015 0.93 0.95 0.87 0.90 1,958,400 0.90
May 1, 2015 0.88 0.90 0.85 0.87 1,455,000 0.87
Apr 30, 2015 0.87 0.88 0.83 0.88 1,845,200 0.88
Apr 29, 2015 0.80 0.82 0.76 0.81 4,300,900 0.81
Apr 28, 2015 0.92 0.93 0.81 0.81 4,763,900 0.81
Apr 27, 2015 1.01 1.02 0.89 0.92 2,491,100 0.92
Apr 24, 2015 1.03 1.03 0.96 0.99 2,518,200 0.99
Apr 23, 2015 1.03 1.04 0.96 0.98 4,808,700 0.98
Apr 22, 2015 1.05 1.08 0.90 0.96 6,241,100 0.96
Apr 21, 2015 1.12 1.13 1.03 1.05 4,078,100 1.05
Apr 20, 2015 1.13 1.13 1.09 1.12 1,396,100 1.12
Apr 17, 2015 1.16 1.16 1.10 1.11 2,474,600 1.11
Apr 16, 2015 1.15 1.18 1.12 1.14 2,916,100 1.14
Apr 15, 2015 1.11 1.15 1.04 1.15 5,745,300 1.15
Apr 14, 2015 1.17 1.18 1.11 1.12 4,047,300 1.12
Apr 13, 2015 1.22 1.23 1.13 1.17 5,421,500 1.17
Apr 10, 2015 1.26 1.26 1.19 1.24 2,671,700 1.24
Apr 9, 2015 1.30 1.31 1.23 1.26 5,697,500 1.26
Apr 8, 2015 1.39 1.39 1.31 1.32 4,604,600 1.32
Apr 7, 2015 1.40 1.44 1.33 1.35 8,450,400 1.35
Apr 6, 2015 1.40 1.45 1.31 1.32 19,769,600 1.32
Apr 2, 2015 1.18 1.18 1.12 1.16 1,471,300 1.16
Apr 1, 2015 1.18 1.20 1.09 1.17 3,317,800 1.17
Mar 31, 2015 1.21 1.22 1.18 1.18 1,270,800 1.18
Mar 30, 2015 1.21 1.22 1.17 1.20 1,468,600 1.20
Mar 27, 2015 1.20 1.21 1.16 1.19 1,173,800 1.19
Mar 26, 2015 1.19 1.22 1.16 1.18 1,745,300 1.18
Mar 25, 2015 1.30 1.35 1.18 1.19 3,686,900 1.19
Mar 24, 2015 1.23 1.28 1.20 1.24 3,043,700 1.24
Mar 23, 2015 1.27 1.27 1.16 1.20 2,508,700 1.20
Mar 20, 2015 1.25 1.26 1.15 1.19 2,865,000 1.19
Mar 19, 2015 1.25 1.28 1.21 1.22 2,149,100 1.22
Mar 18, 2015 1.30 1.32 1.18 1.21 4,031,400 1.21
Mar 17, 2015 1.30 1.36 1.25 1.32 4,391,700 1.32
Mar 16, 2015 1.20 1.39 1.20 1.37 8,731,700 1.37
Mar 13, 2015 1.17 1.23 1.03 1.20 6,936,200 1.20
Mar 12, 2015 1.15 1.20 1.12 1.15 3,754,100 1.15
Mar 11, 2015 1.40 1.47 1.12 1.19 12,485,800 1.19
Mar 10, 2015 1.24 1.41 1.20 1.35 13,281,300 1.35
Mar 9, 2015 1.16 1.26 1.11 1.24 8,772,000 1.24
Mar 6, 2015 1.16 1.18 1.10 1.11 2,900,900 1.11
Mar 5, 2015 1.14 1.21 1.09 1.16 5,128,700 1.16
Mar 4, 2015 1.10 1.17 1.06 1.14 6,817,800 1.14
Mar 3, 2015 1.09 1.27 1.04 1.20 8,325,100 1.20
Mar 2, 2015 1.08 1.16 0.97 1.12 9,044,700 1.12
Feb 27, 2015 1.34 1.42 1.08 1.12 35,132,600 1.12
Feb 26, 2015 0.78 1.25 0.78 1.13 44,480,800 1.13
Feb 25, 2015 0.78 0.79 0.69 0.72 4,211,700 0.72
Feb 24, 2015 0.73 0.82 0.70 0.73 17,326,600 0.73
Feb 23, 2015 0.57 0.66 0.56 0.65 5,177,900 0.65
Feb 20, 2015 0.57 0.57 0.53 0.55 2,262,800 0.55
Feb 19, 2015 0.61 0.64 0.55 0.55 3,779,300 0.55
Feb 18, 2015 0.48 0.63 0.47 0.59 8,456,700 0.59
Feb 17, 2015 0.47 0.48 0.46 0.47 973,100 0.47
Feb 13, 2015 0.46 0.48 0.46 0.47 353,600 0.47
Feb 12, 2015 0.46 0.47 0.45 0.47 335,700 0.47
* Close price adjusted for dividends and splits.

So- this MMT stuff -really food for the chartists :whistle:
Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

A Magical Mystery Tour- Part II? 16 Mar 2016 07:35 #6650

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115
But for the fundies there was the most impressive news flow (from a view point of concentration in a short time frame) for quite some time :whistle:

Apr 23, 2015 Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds Combining Thermal Burn and Radiation Exposure
Apr 13, 2015 Cytori Provides Twelve Month Data Update on Scleradec-I Trial
Apr 07, 2015 Cytori Granted Orphan Drug Status for Cellular Therapeutic in European Union
Apr 06, 2015 Cytori and Lorem Vascular Receive Regulatory Clearance in China
Mar 25, 2015 Cytori Launches Celase® GMP Product
Mar 23, 2015 Cytori Presents Thermal Burn Data at the 2015 American Burn Association Meeting
Mar 12, 2015 Cytori Reports Fourth Quarter and Full Year 2014 Business and Financial Results
Mar 11, 2015 Investor Note: Cytori to Webcast Fourth Quarter and 2014 Financial Results on March 12, 2015
Mar 06, 2015 Cytori to Provide Corporate Update at the 27th Annual ROTH Conference in Laguna Niguel, California
Mar 04, 2015 Cytori Provides Business Update Along with Top-line Unaudited 2014 Financial Results at the Cowen and Company 35th Annual Health Care Conference in Boston
Mar 03, 2015 Cytori to Provide Corporate Update at Cowen and Company 35th Annual Health Care Conference
Feb 26, 2015 FDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites
Feb 24, 2015 Cytori Receives Positive European Opinion on Orphan Drug Status
Feb 17, 2015 Cytori Begins Enrollment in ACT-OA: US Phase II Trial for Knee Osteoarthritis
Feb 10, 2015 Enrollment Begins European Knee Meniscus Injury Pilot Trial to Evaluate Cytori Cell Therapy
Feb 02, 2015 Investor Note: Cytori Updates Investors on Recent FDA Draft Guidance on Cell Therapy and Adipose Tissue


Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

A Magical Mystery Tour- Part II? 16 Mar 2016 08:24 #6652

  • angryharry
  • angryharry's Avatar
  • Offline
  • Junior Boarder
  • Junior Boarder
  • Posts: 35
  • Thank you received: 3
i found it interesting when KOOL (another of Sabby's holdings from what I understand) had a magical mystery jump (no news) not long before its reverse split. i'm thinking that, if anything, we may see a jump to reduce the reverse split ratio but i highly highly doubt we'll see another magical rise to above a dollar -- the percentage at this point just seems way too high.

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 19 Mar 2016 08:01 #6672

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115
Oh well- there are no more takers so I assume nobody has any hope left that any type of MMT will occur going forward.. :whistle: :bye:

Maybe that is correct, maybe not - when I look at the news flow since January, I have a feeling they tried again....in early 2016

Mar 03, 2016 Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results
Feb 22, 2016 Data Reports Sustained Benefit at Two Years with Single Administration Cytori Cell Therapy for Scleroderma
Feb 19, 2016 Cytori Management to Discuss Scleroderma Clinical Trial Findings
Feb 18, 2016 Japan Commercial UpdateFeb 10, 2016Scleroderma Two Year Data to be Presented at the 4th Systemic Sclerosis World Congress
Feb 08, 2016 Cytori Reports Interim Data on U.S. Phase II Osteoarthritis Trial
Feb 04, 2016 Cytori Provides Latest Corporate Update at Source Capital Conference
Feb 03, 2016 Cytori Cell Therapy Safe and Potentially Effective in EU Phase I Erectile Dysfunction Trial
Feb 02, 2016 Further Details on Cytori’s Managed Access Program in EMEA
Jan 25, 2016 Cytori Update on Its U.S. Phase III Scleroderma Trial
Jan 21, 2016 Cytori Partner Kerastem Expands US Phase II Trial for Early Stage Hair Loss
Jan 19, 2016 Enrollment Begun on Phase II Clinical Trial in Crohn’s Disease
Jan 12, 2016 Cytori Enters Agreement with Idis to Launch Managed Access Program in EMEA
Jan 05, 2016 Cytori Therapeutics to Provide Corporate Update at 2016 Biotech Showcase™


Just like the year before- they presented at two conferences- Cowen and Roth in 2015- Biotech Showcase and Source Capital this year.

In my mind Hedrick personally screwed up any momentum they had on February 8, when he released the OA interim results which clinic was NOT powered for statistical significance , by including in the announcement :

The pre-specified primary endpoint, pain on walking at 12 weeks, as measured by a single question from the Knee Injury and Osteoarthritis Outcome Score (KOOS) did not obtain statistical significance.


Of course- that was utterly stupid and he just should have mentioned an average number of percentage pain reduction of the treated patients- than we would have had 25% plus instead of 25% minus. :evil: :bash: :bash:

Anyway- we need a financial announcement i.e. partner deal- I am still positively minded that this could work- otherwise the refusal of the partnership offer for scleroderma in the US should really be viewed as "negligence" and could be a good reason for all shareholders to demand for heads rolling. :bang: :bang:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

A Magical Mystery Tour- Part II? 19 Mar 2016 09:34 #6673

  • cytxer
  • cytxer's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 347
  • Thank you received: 25
Fas, Your last post sounds like you want Marc to hide the truth and not share all the info so the price can go up?

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 20 Mar 2016 00:55 #6674

  • joeycav11
  • joeycav11's Avatar
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 130
  • Thank you received: 41
Hi Fas, as an optimist I could see the stock hitting a buck on the back of a total repricing of the sector. All the stem companies have been beaten down to historical lows. So if MESO, ATHX or others take off we could see a big move over a buck.
Hopefully management has other catalysts in the works as I believe they do.
If they lasted this long I don't see them going bankrupt now when the science is getting so close to approvals... And Japan is putting some money in now.

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 20 Mar 2016 14:23 #6675

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 889
  • Thank you received: 148
Fas,

I have to disagree with you on this one. The OA data didn't show anything. There is often a placebo effect when pain is the measurement. You can't put lipstick on a pig once the cell therapy arm did no better than the placebo. I still think they may have dosed too low. As I mentioned a couple of times, the high dose in the Korean study, now in Phase II in the U.S. was 100MM autologous cultured aMSCs. In this Korean study there was a clear dose rrelated response and only the 100MM dose grew substantial high quality cartilage.

There is one twist to this that hasn't been mentioned here and wasn't disclosed for fear of tainting the rest of the trial. I understand that the placebo group had a much higher incidence of NASID use. There was debate as to whether this should be disclosed in the press release. My view is that it should have, given the desperate capital situation. However, I doubt it would have made much of a difference. Any attempt to make something sound better than reality would have backfired, IMHO, and it is not clear to me how you can quantify pain relief from NASIDs to get meaningful data.

If you want to place blame, look at the person who designed the trial. It seems that it was poorly designed because, IMHO, if done properly this therapy should work. Now 48 week cartilage growth looks iffy due to the relatively low dosage used compared to the Korean trial and I don't believe there were an excessive number of passages that would have diluted efficacy so much that maybe 40Mm fresh ADRCs might be expected to do perform similarly.

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 20 Mar 2016 19:29 #6676

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2825
  • Thank you received: 202
WST...agree but neutral on the dosing aspect.

I also feel there is a real risk of total failure with this OA trial. :puke:

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 21 Mar 2016 01:18 #6677

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 387
  • Thank you received: 196
Fas, I agree that the Hedrick comment concerning the OA trial not obtaining statistical significance was a serious mistake given that the trial was not powered to do so, and given the well documented placebo effect.

Given that the other trial endpoints gave an indication of trending efficacy and possible eventual statistical significance the negative comment detracted from what in my opinion was essentially positive news. The pendulum has swung too far.
CC would have put a positive spin on the news no doubt, but political correctness has MH going to the other extreme. :cry:

As time goes by the placebo effect should fade. If as WST states there was substantialy higher use of NASID in the placebo arm then I believe we are looking at a positive outcome. If this is accompanied by MRI confirmation that cartilage growth exists at 48 weeks we have a winner.

A phase III trial can be structured in a number of ways. If we see greater cartilage growth in the high dose cohort then why not introduce an additional higher ADRC cell cohort in the phase III . We could also introduce a booster shot at 6 months instead of just a single injection. How about using an adjuvant to stimulate cartilage growth prior to injection? The question is who and how will we pay for this trial ??????

The possibilities are countless. One thing is for sure any of the above options are surely cheaper than culturing autologous MS cells. :grin: I can see a Celution device in every hospital and doctors surgery ......... I am not sure I can see certified cGMP facilities being as common, cheap or consistent in quality output.

As for the Korean study, the results are further confirmation that ADRC are the way forward. Whether Celution or cultured will succeed will no doubt eventually be determined. I however do not want to put too much credence in a non placebo controlled trial of only 12 patients.

We don't know the difference in cartilage production between the three groups.......... two of which had only 3 patients each as opposed to the high cell cohort of 12 patients. Consider if two of the patients in each of the low dose cohorts was of advanced years....... what sort of effect would that have on the results ? :KO:

I'll stick with CYTX for now ....... I am nothing if not consistent ......... of course I may be a fool :bash: ....... time will tell.

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 21 Mar 2016 07:42 #6678

  • DOV
  • DOV's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 347
  • Thank you received: 194
Another possibility is that Cytori drops pursuit of the OA application due to no partner and the crowded field. Every day it seems, I get another google alert about fat stem cells being used to treat OA. There must be at least 10 trials going on now. Cytori wasted so much time during the Calhoun years that Cytori no longer has a lead in producing data. The one area where Cytori does have a lead is Scleroderma and they may cut expenses in OA to achieve break-even by the end of 2018.

On the other hand, any potential partner is getting full trial disclosure at 24 weeks under a NDA. If the trial data does not bring in a partner, then the trial is a failure.

Stockholder's judge 2015 as one of the worst years in the company's history. Hedrick judges it as one of the best. His perspective is only looking at the controllables.

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 21 Mar 2016 08:14 #6679

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115

Wall Street Titan wrote: Fas,

I have to disagree with you on this one. The OA data didn't show anything. There is often a placebo effect when pain is the measurement. You can't put lipstick on a pig once the cell therapy arm did no better than the placebo. I still think they may have dosed too low. As I mentioned a couple of times, the high dose in the Korean study, now in Phase II in the U.S. was 100MM autologous cultured aMSCs. In this Korean study there was a clear dose rrelated response and only the 100MM dose grew substantial high quality cartilage.
.


No problem to disagree WST, but one thing you are wrong- the key message was NOT that that they did not do better as placebo- it said simply the difference was not statistically significant.

The interim top-line data show the following:

-The randomization is relatively balanced among the three treatment groups: low dose, high dose and placebo.
-Intra-articular application of a single dose of ECCO-50 appears to be safe and feasible in an outpatient day-surgery setting. No complications occurred related to the fat harvest, cell processing or cell delivery.
-A significant placebo response was observed, similar to that demonstrated in other OA trials.
-The pre-specified primary endpoint, pain on walking at 12 weeks, as measured by a single question from the Knee Injury and Osteoarthritis Outcome Score (KOOS) did not obtain statistical significance.
-Key secondary endpoints include the total and sub-scores of the KOOS, patient assessment of knee pain, knee stability, osteoarthritis activity and osteoarthritis damage, use of as-needed pain medication, pain while walking 50 feet and health status as measured by the SF-36. Consistent trends were observed suggesting improvement in the cell treated group relative to the placebo group at the 12 and 24 week time periods for patient reported outcomes.
-Both high dose and low dose of ECCO-50 performed similarly.


I presume we have kinda of a situation with 50% improvement in pain in placebo and 60% or more in treated at 24 weeks which is not statistically significant. I think we simply should wait. They surely must have tested the cells in the tissue microenvironment of the knee and have come out again with these doses as most likely sufficient for the local endogenous receptors. I would think this is sufficient too....there is the famous threshold.. :grin:

Anyway- there was recently a very interesting article by Mercola on "Healing of the Power of Placebo" - you can visit it : HERE

The article had a video too, which was a documentary on scientific studies of the placebo effect- the second example from an orthopedic doc treating spines with cement or something was really amazing.....that should tell you what the power of the mind is, but...

but we ..as Stem cell idiots know more than those doctors do- we know that sham surgeries according to Caplan´s theories, which are pretty sure to be correct, act like inflicted injury- i.e. tissue injury creates a spontaneous cascade of activated pericytes from the outer vessel of local arteries involved in the injury... so even when no cells are injected- local cells are activated, which surely explains a part of the placebo response.

I agree with DOV- success means for OA, getting a US partner. Last CC Hedrick said- that a OA partner is now the number 3 in the sequence - he should know. :whistle:
The following user(s) said Thank You: mtpinman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

A Magical Mystery Tour- Part II? 21 Mar 2016 09:48 #6681

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115

DOV wrote: Another possibility is that Cytori drops pursuit of the OA application due to no partner and the crowded field. Every day it seems, I get another google alert about fat stem cells being used to treat OA. There must be at least 10 trials going on now. Cytori wasted so much time during the Calhoun years that Cytori no longer has a lead in producing data. The one area where Cytori does have a lead is Scleroderma and they may cut expenses in OA to achieve break-even by the end of 2018.

On the other hand, any potential partner is getting full trial disclosure at 24 weeks under a NDA. If the trial data does not bring in a partner, then the trial is a failure.

Stockholder's judge 2015 as one of the worst years in the company's history. Hedrick judges it as one of the best. His perspective is only looking at the controllables.


Yes- the fact that Cytori was very late (as usual- same in respect of auto-immune disorders like scleroderma.. :cry: ) is poor performance of what should be the market leader.. :bash:

One thing stands out with Cytori though- even though they want folks to realize they produce a cellular product, which is totally correct of course, the regulatory pathway is a PMA device, whilst all others is IND. This makes a tremendous difference, even though Hedge isnt sure about that...these guys below know...

1. Johnson & Johnson (The combination Depuy and Synthes of course)
2. Stryker
3. Zimmer
4. Biomet
5. Medtronic
6. Smith & Nephew
7. Arthrex
8. NuVasive

and for Cytori that advantage was even so substantial that they opted NOT to apply for Scleroderma as an orphan disorder, but do their usual (with that I mean all future pivotal/P III clinics) PMA pivotal pathway :bye:

It took from early 2007 until late 2009 for CBER to decide that as Calhoun told me in May 2010. That was based on the Request For Designation they filed in 2007. At least that time frame was not totally wasted... :evil: And just as an anecdote- the RFD´s filed by Ricardo Rodriguez and Chris Centeno for use of manual produced fat cells in plastic surgery resp . orthopedics (which were filed roughly a year later in 2008, but took also 2,5 years for CBER to make their minds up) resulted both for both procedures to be judged as a drug i.e. IND. :KO:
The following user(s) said Thank You: mtpinman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

A Magical Mystery Tour- Part II? 21 Mar 2016 11:14 #6682

  • Claus
  • Claus's Avatar
  • Offline
  • Fresh Boarder
  • Fresh Boarder
  • Posts: 1
  • Thank you received: 0
Could this be a possible case?

Cytori closes a deal for scleroderma in Europe and receives 10 Million $. That could bring the stock price up to 0,30 $. A split 20:1 would bring the stock to 6 $. A capital increase of 5 million new shares means 25-30 Million in cash. Together with a increase in revenues in Japan, all in all could be enough to achieve break-even.

It´s not a dream case, but in my opinion likely to happen :yawn:

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 21 Mar 2016 11:19 #6683

  • CalhounDoppelganger
  • CalhounDoppelganger's Avatar
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 160
  • Thank you received: 20

Claus wrote: Could this be a possible case?

Cytori closes a deal for scleroderma in Europe and receives 10 Million $. That could bring the stock price up to 0,30 $. A split 20:1 would bring the stock to 6 $. A capital increase of 5 million new shares means 25-30 Million in cash. Together with a increase in revenues in Japan, all in all could be enough to achieve break-even.

It´s not a dream case, but in my opinion likely to happen :yawn:


The reason why this will not happen is as follows:
  • I plan on winning the lotto in Dubai. Then I will make a hostile takeover bid of $0.45 per share in order to take this away from the evil Dr. Hedrick. Then we relaunch another IPO under Calhoun's Magical Fatrifuge. (copyrighted, naturally)

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 21 Mar 2016 14:10 #6684

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 889
  • Thank you received: 148
Fas,

"No problem to disagree WST, but one thing you are wrong- the key message was NOT that that they did not do better as placebo- it said simply the difference was not statistically significant".

I guess I should have been more specific because it was my intent to say that the treatment arm did not do better than the placebo on a statistically significant basis but I guess I can't expect you to read my mind.

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 21 Mar 2016 19:29 #6685

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2825
  • Thank you received: 202
DOV
Curious to see what your latest est. show for OA in 2020

Fas
***even though Hedge isnt sure about that***
LOL

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 22 Mar 2016 12:58 #6686

  • forgotmorthanuno
  • forgotmorthanuno's Avatar
  • Offline
  • Senior Boarder
  • Senior Boarder
  • Posts: 73
  • Thank you received: 44
I stated multiple times that 142 was major resistance. it still is. look at the retest in the charts. There's even a new number that's a hurdle - just below 40 cents. we need 2 consecutive closes above 40 cents to relaunch an attack on 142. 10.01 is the all time high and was retested at 950. it's the real resistance but irreleveant currently.
40
142
405
1001

in that order...........0 is major support
These fucks are incompetent........maybe schleroderma saves the company ......even OA.......F

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 22 Mar 2016 13:26 #6687

  • fatboy
  • fatboy's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 416
  • Thank you received: 77
Forgot said

0 is major support
These fucks are incompetent


If Hedrick and Tiago can sell the reverse split and get enough suckers to buy in you may be able to start charting the next downcycle. Til then you may as well throw darts a a board - as long as the numbers do not get above twenty cents. If they don't get positive results on scleroderma all bets are off. Remember according to Hedrick the last year has been one of the best in the history of the company. If that's the case I can't wait to see the next year!

Please Log in or Create an account to join the conversation.

A Magical Mystery Tour- Part II? 27 Apr 2016 05:15 #6866

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3337
  • Thank you received: 1115

fas wrote: Oh well- there are no more takers so I assume nobody has any hope left that any type of MMT will occur going forward.. :whistle: :bye:

Maybe that is correct, maybe not - when I look at the news flow since January, I have a feeling they tried again....in early 2016

Mar 03, 2016 Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results
Feb 22, 2016 Data Reports Sustained Benefit at Two Years with Single Administration Cytori Cell Therapy for Scleroderma
Feb 19, 2016 Cytori Management to Discuss Scleroderma Clinical Trial Findings
Feb 18, 2016 Japan Commercial UpdateFeb 10, 2016Scleroderma Two Year Data to be Presented at the 4th Systemic Sclerosis World Congress
Feb 08, 2016 Cytori Reports Interim Data on U.S. Phase II Osteoarthritis Trial
Feb 04, 2016 Cytori Provides Latest Corporate Update at Source Capital Conference
Feb 03, 2016 Cytori Cell Therapy Safe and Potentially Effective in EU Phase I Erectile Dysfunction Trial
Feb 02, 2016 Further Details on Cytori’s Managed Access Program in EMEA
Jan 25, 2016 Cytori Update on Its U.S. Phase III Scleroderma Trial
Jan 21, 2016 Cytori Partner Kerastem Expands US Phase II Trial for Early Stage Hair Loss
Jan 19, 2016 Enrollment Begun on Phase II Clinical Trial in Crohn’s Disease
Jan 12, 2016 Cytori Enters Agreement with Idis to Launch Managed Access Program in EMEA
Jan 05, 2016 Cytori Therapeutics to Provide Corporate Update at 2016 Biotech Showcase™


Just like the year before- they presented at two conferences- Cowen and Roth in 2015- Biotech Showcase and Source Capital this year.

In my mind Hedrick personally screwed up any momentum they had on February 8, when he released the OA interim results which clinic was NOT powered for statistical significance , by including in the announcement :

The pre-specified primary endpoint, pain on walking at 12 weeks, as measured by a single question from the Knee Injury and Osteoarthritis Outcome Score (KOOS) did not obtain statistical significance.


Of course- that was utterly stupid and he just should have mentioned an average number of percentage pain reduction of the treated patients- than we would have had 25% plus instead of 25% minus. :evil: :bash: :bash:

Anyway- we need a financial announcement i.e. partner deal- I am still positively minded that this could work- otherwise the refusal of the partnership offer for scleroderma in the US should really be viewed as "negligence" and could be a good reason for all shareholders to demand for heads rolling. :bang: :bang:


When one looks at the chart of the last month, it is pretty striking that we see a roughly 100% PPS increase although the news was rather meager...:

first chart -




the news was extremely meager for a "magical Mystery Tour similar to 2015-

Apr 18, 2016- Cytori Strengthens Global Patent Portfolio
Apr 14, 2016- Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American Burn Association Meeting
Apr 06, 2016- 2016 Investors Note about a possible shareholders rights offering..

Somehow I have the feeling that it is not impossible that we are being heavily manipulated for some reason for which I have no explanation.. :whistle: or does the market suddenly see a lot of value in Cytori similarly to what I have been seeing all these years and the "boom" is coming- dont tell me its the new model and trust and confidence in Hedrick to achieve what he says- that confidence never was there and still isnt there. :really:

So what is it?
Attachments:
The following user(s) said Thank You: mtpinman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
  • 2
Time to create page: 1.523 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites